Drugs / Essential oils
Essential oils
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT04410159 | Jun 2020 | COVID-19 | Islamic Science University of Malaysia | Completed | No outcome recorded |
| Phase 2 | NCT03000595 | Jun 2018 → Jan 2019 | atopic eczema | Santalis Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03158974 | Aug 2017 → Jun 2018 | anogenital human papillomavirus infection | ViroXis Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03000608 | May → Dec 2017 | psoriasis | Santalis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02399228 | Oct 2015 → May 2017 | mucositis | Santalis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 44 trials · 1 met primary | ||||||
| Phase 4 | NCT05583240 | Apr 2021 → Apr 2023 | substance withdrawal syndrome | Etablissement Public de Santé Barthélemy Durand | Unknown | No outcome recorded |
| Phase 4 | NCT02946814 | Oct → Nov 2016 | Athrombia, essential | University of Santiago de Compostela | Unknown | No outcome recorded |
| Phase 4 | NCT02884817 | Sep → Oct 2015 | gingivitis | University of Oslo | Completed | No outcome recorded |
| Phase 4 | NCT02124655 | Sep 2012 → Jun 2013 | periodontitis | University of Santiago de Compostela | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT04733196 | Oct → Dec 2020 | gingivitis | Plovdiv Medical University | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT02024581 Comparator | Feb 2016 → Sep 2017 | molluscum contagiosum | ViroXis Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT01286441 Comparator | Nov 2012 → Apr 2014 | common wart | ViroXis Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03146390 Comparator | May → Jul 2017 | periodontitis | University of Santiago de Compostela | Unknown | No outcome recorded |
| Phase 4 | NCT02946801 Comparator | Nov 2016 | Athrombia, essential, periodontitis | University of Santiago de Compostela | Unknown | No outcome recorded |
| Phase 4 | NCT02267239 Comparator | Oct → Nov 2014 | gingivitis, periodontitis | University of Santiago de Compostela | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Essential oils | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04410159 ↗ |
| Known as | East Indian Sandalwood Oil | “A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance.” NCT02399228 ↗5“SAN021 is a serum containing 10% East Indian Sandalwood Oil.” NCT03000608 ↗ “A cream containing 5% East Indian sandalwood oil (EISO).” NCT03000595 ↗ “East Indian Sandalwood Oil (EISO)” NCT01286441 ↗ |
| Known as | EISO | “A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance.” NCT02399228 ↗3“Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids” NCT03158974 ↗ “A cream containing 5% East Indian sandalwood oil (EISO).” NCT03000595 ↗ “East Indian Sandalwood Oil (EISO)” NCT01286441 ↗ |
| Known as | SAN007 | “This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation)...” NCT03000595 ↗ |
| Known as | SAN021 | “SAN021 is a serum containing 10% East Indian Sandalwood Oil.” NCT03000608 ↗ |
| Route | Topical | “applied topically twice daily” NCT01286441 ↗ |